INTRODUCTION
Extensive-stage small-cell lung cancer (SCLC) occurs almost exclusively in heavy smokers and accounts for approximately 15% of all lung cancers. 1 The prognosis is generally poor, with a median overall survival (OS) of 8 to 12 months and a 2-year OS rate of 5%.
2, 3 Although response rates of 50% to 80% are achieved in first-line treatment with a platinum and etoposide chemotherapy doublet, progression occurs universally, and outcomes with second-line treatments are poor. 3, 4 Topotecan remains the recommended second-line therapy in the United States (National Comprehensive Cancer Network), European Union (European Society of Medical Oncology), and Japan (Japanese Society of Medical Oncology), 5, 6 even though the response rate is in the 15% to 20% range and responses are generally of short duration. 3 In addition, amrubicin is an alternative second-line therapy approved in Japan. 7 Tumors can evade T-cell-mediated destruction by upregulating programmed death ligand 1 (PD-L1), [8] [9] [10] which interacts with the inhibitory receptor programmed death 1 (PD-1) expressed on tumorinfiltrating T cells and leads to their functional inactivation.
11,12
Blockade of the interaction of PD-1 or PD-L1 with monoclonal antibodies has led to durable objective responses in a spectrum of solid and hematologic malignancies. 13 Pretreatment tumor PD-L1 expression was associated with response to PD-1 and PD-L1 inhibition and was identified in post hoc analyses of specimens collected in the initial trials; the main focus was on non-small-cell lung cancer (NSCLC), melanoma, and renal cell cancer. These data have been confirmed in subsequent, larger cohorts of patients with cancer. [14] [15] [16] [17] Pembrolizumab is a highly selective humanized monoclonal antibody that binds to the PD-1 receptor and directly blocks the interaction between PD-1 and its ligands, thereby enhancing the function of tumor-directed T cells, mediating tumor destruction. 10 Pembrolizumab has demonstrated robust antitumor activity and a favorable safety profile in multiple tumor types, and it is currently approved in more than 60 countries for one or more of the following indications: unresectable or metastatic melanoma; metastatic high PD-L1-expressing (tumor proportion score [TPS] $ 50%) NSCLC with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations and no prior systemic chemotherapy treatment for metastatic NSCLC; metastatic, PD-L1-expressing (TPS $ 1%) NSCLC with disease progression during or after platinum-containing chemotherapy; in combination with pemetrexed and carboplatin, as first-line treatment of patients with metastatic nonsquamous NSCLC; and recurrent or metastatic head and neck squamous cell carcinoma with disease progression during or after platinum-containing chemotherapy.
KEYNOTE-028 is an open-label, phase Ib multicohort (20 cohorts) study that explored the safety and efficacy of pembrolizumab in patients with PD-L1-positive tumors. Here, we report the safety, efficacy, and biomarker results from the SCLC cohort of KEYNOTE-028.
METHODS

Study Design
KEYNOTE-028 (ClinicalTrials.gov identifier: NCT02054806) was designed to examine the safety and efficacy of pembrolizumab in patients with advanced solid tumors. Patients received pembrolizumab 10 mg/kg every 2 weeks for 24 months or until documented disease progression, intolerable toxicity, physician decision to discontinue, or withdrawal of consent occurred. The study was conducted in compliance with local and/or national regulations and in accordance with the Declaration of Helsinki. All patients signed written informed consent to participate.
Study Population
Patients eligible for enrollment in the extensive-stage SCLC cohort were 18 years of age or older and had histologically confirmed SCLC or pulmonary neuroendocrine tumor that had failed standard therapy. Patients had tumors that expressed PD-L1, had measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1); an Eastern Cooperative Oncology Group performance status of 0 or 1; and adequate hematologic, renal, hepatic, and coagulation laboratory values. Tumor PD-L1 expression was required to be eligible for treatment in the study; it was evaluated in archival or fresh tumor samples by a central laboratory (QualTek Molecular Laboratories, Goleta, CA) by using a prototype assay and the 22C3 antibody (Merck & Co, Kenilworth, NJ).
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Detailed methods of the PD-L1 immunohistochemistry assay were described before 14 ; PD-L1 positivity was defined by membranous PD-L1 expression in $ 1% of tumor and associated inflammatory cells or positive staining in stroma.
14 An adequate sample must have had at least 50 viable neoplastic cells overall. Otherwise, the sample was reported as not evaluable.
Key exclusion criteria were previous treatment with PD-1/PD-L1 inhibitors, concurrent malignancy that required treatment (except basal cell or squamous cell carcinomas of the skin or in situ cervical cancer), known active brain metastases (treated brain metastases that were stable for $ 4 weeks before the first dose of pembrolizumab was permitted) or carcinomatous meningitis, active autoimmune disease that required systemic corticosteroids, and interstitial lung disease or history of pneumonitis that required systemic corticosteroids.
Outcomes
Patients were evaluated every 8 weeks with radiographic imaging to assess response to treatment for the first 6 months and every 12 weeks thereafter. The primary end points were safety and tolerability. The primary efficacy end point was objective response rate (ORR) assessed by RECIST v1.1 per investigator review. Secondary end points included progression-free survival (PFS), overall survival (OS), and duration of response. Adverse events (AEs) were monitored throughout the trial and graded in severity according to the guidelines outlined in the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
Statistical Analyses
Each cohort in KEYNOTE-028 planned to enroll approximately 22 to 25 patients. A sample size of 22 evaluable patients in this cohort was calculated to provide 80% power to demonstrate that the best ORR exceeded 10% at an overall one-sided a level of 8%. For investigatorassessed ORR, the point estimate, the 95% CI that was based on the binomial exact CI method, and P values that were based on exact binomial distribution were provided. PFS, OS, and duration of response data were calculated with the Kaplan-Meier method.
All efficacy analyses were conducted on all patients who received at least one dose of pembrolizumab and had measurable disease at baseline per RECIST v1.1. Safety analyses were conducted on all patients who received at least one dose of study medication and had at least one followup assessment. The data cutoff for this report was June 20, 2016 .
RESULTS
Between March 2014 and May 2015, 163 patients with extensivestage SCLC were screened for enrollment, and 145 had biopsy samples for PD-L1 evaluation. Twelve samples were from fresh or newly obtained tissue, and the remainder were from archival samples. Forty-six patients (31.7%) tested positive for PD-L1 expression, and 24 patients were treated. Of the 46 patients who were positive for PD-L1, 15 patients did not meet inclusion criteria. Reasons for not meeting inclusion criteria were as follows: patient did not consent (n = 7), patient did not meet Eastern Cooperative Oncology Group performance status requirements (n = 7), and patient did not have SCLC (n = 1). The CONSORT diagram is shown in Figure 1 . The median age of treated patients was 60.5 years (range, 41 to 80 years), and 14 (58.3%) of 24 patients were men. Baseline and disease characteristics are listed in Table 1 . The median follow-up duration was 9.8 months (range, 0.5 to 24.4 months). All 24 patients had received prior chemotherapy for SCLC; 21 (87.5%) of 24 patients had two or more prior lines of therapy. All patients had received prior platinum plus etoposide as first-line treatment, and 11 (45.8%) of 24 patients had received second-line treatment with either topotecan or irinotecan.
Safety
AEs regardless of attribution were experienced by all patients (Appendix Table A1 , online only); the most common events were asthenia (n = 7), fatigue (n = 7), cough (n = 6), arthralgia (n = 5), diarrhea (n = 5), insomnia (n = 5), and rash (n = 5). Treatmentrelated AEs were seen in 16 (66.7%) of 24 patients (Table 2) ; the most common events were arthralgia, asthenia, and rash (n = 4 each) as well as diarrhea and fatigue (n = 3 each). Eight patients (33.3%) had grade 3 to 5 AEs, two of whom had AEs that were considered related to treatment. One patient experienced grade 3 bilirubin elevation, and another patient experienced grade 3 asthenia and grade 5 colitis/intestinal ischemia. The first patient was a 65-year-old man with SCLC and liver metastasis. The patient developed grade 3 increased bilirubin with no other associated liver function abnormalities after two cycles of pembrolizumab, and the investigator reported it to be possibly related to treatment. The patient subsequently discontinued treatment because of disease progression. The second patient was a 58-year-old woman with previous history of sleeve gastrectomy; she received a total of 11 cycles of pembrolizumab. The patient was initially hospitalized after her tenth treatment with abdominal pain, nausea, and vomiting and was discharged home with a diagnosis of food intolerance. The patient received her eleventh treatment of pembrolizumab and was admitted to the hospital again with abdominal pain. The diagnostic workup there included a rectal biopsy that indicated chronic colitis. The patient subsequently was treated with systemic corticosteroids and discharged home. The patient was readmitted to another hospital a few weeks later with diffuse abdominal pain and septic shock; mesenteric ischemia resulted in death. The cause of the colitis and intestinal ischemia was reported as probably related to pembrolizumab. One other patient had AEs with immune-related etiology: grade 2 autoimmune thyroiditis. Another patient had a grade 1 infusion-related reaction that occurred during cycle 2, which resolved upon interruption of pembrolizumab. It recurred during cycle 3 and again resolved with pembrolizumab interruption. The patient subsequently discontinued treatment because of progression.
Efficacy
The confirmed ORR (investigator assessed per RECIST v1.1) was 33.3% (95% CI, 15.6% to 55.3%; Table 3 ). One patient (4.2%) experienced a complete response (CR), seven patients (29.2%) had partial responses (PRs), and one patient (4.2%) had stable disease (SD) for less than 6 months. Thirteen patients (54.2%) experienced disease progression as the best overall response. Changes in tumor burden from baseline for individual patients are shown in Figure 2A .
The median time to response was 2.0 months (range, 1.7 to 3.7 months), and the median duration of response was 19.4 months (range, $ 3.6 to $ 20.0 months; Table 3 ; Fig 2B) . The responses were durable, and three patients remained on treatment with ongoing responses at the time of data cutoff (Fig 2C) .
The median PFS was 1.9 months (95% CI, 1.7 to 5.9 months); the 6-and 12-month PFS rates were 28.6% and 23.8%, respectively (Table 3 ; Fig 3A) . The median OS was 9.7 months (95% CI, 4.1 months to not reached); the 6-and 12-month OS rates were 66.0% and 37.7%, respectively (Table 3 ; Fig 3B) .
DISCUSSION
This study is, to our knowledge, the first report to evaluate the immune checkpoint inhibitor pembrolizumab in patients with heavily pretreated (87.5% with two or more lines of prior therapy; 37.5% with three or more) extensive-stage SCLC. Pembrolizumab showed clinically meaningful antitumor activity and overall was well tolerated; the safety was consistent with the reported safety profile in other tumor types.
14,15, 19, 20 The patients in this study are from the SCLC cohort of the multicohort KEYNOTE-28 study that assessed the safety and efficacy of pembrolizumab in 20 different PD-L1-expressing tumors. On the basis of early evidence, which suggested that tumor PD-L1 expression has use as a predictive marker for antitumor activity of PD-1 inhibition, 14,16,17 PD-L1 expression was mandatory for participation in the treatment part of this study. Compared with patients who have NSCLC, 14,15 our data suggest that there is a lower prevalence of PD-L1 expression in patients with SCLC (31.7%). This trend is consistent with previous reports that evaluated PD-L1 expression in SCLC specimens.
21 PD-L1 expression has been found to be heterogeneous across solid and hematologic malignancies. 22 Upregulation of PD-L1 has been at least partially attributed to interferon gamma-secreting T cells; this occurrence has been termed adaptive immune resistance, which potentially reflects pre-existing tumordirected T-cell responses.
11,12 Increased pre-existent T-cell inflammation in NSCLC tumors compared with SCLC tumors may account for the differences seen in PD-L1 expression between the two tumor types. However, this has not been systematically explored to date.
The confirmed ORR of 33.3% compares favorably with historical response rates of 7% to 24% for topotecan 24, 25 ; notably, tumor responses were rapid and durable. The median onset of response was 2 months, and the median duration of response was 19.4 months (range, $ 3.6 to $ 20.0 months). The responses were durable, and three patients were still on treatment at the time of data cutoff. This contrasts with the typically short duration of response seen with chemotherapy in this setting. 24, 25 Other immune checkpoint inhibitors, including ipilimumab, an antibody directed against cytotoxic T-lymphocyte-associated protein 4, and the anti-PD-1 antibody nivolumab, have been studied in the treatment of extensive-stage SCLC. Despite some initial activity, addition of single-agent ipilimumab to standard platinum and etoposide chemotherapy in the maintenance setting failed to show improvement in OS in patients with extensive-stage SCLC. 26 The CheckMate 032 trial (ClinicalTrials.gov identifier: NCT01928394) evaluated single-agent nivolumab (n = 98) and nivolumab in combination with ipilimumab (n = 118 in three Abbreviations: CR, complete response; DCR, disease control rate; DOR, duration of response; NR, not reached; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; TTR, time to response. *ORR is CR + PR. †Calculated with the Kaplan-Meier method for censored data. ‡DCR is CR + PR + SD $ 6 months. different dose cohorts) in patients with extensive-stage SCLC. 21 In contrast to this study, CheckMate 032 enrolled patients regardless of PD-L1-expression status. An ORR of 10% (10 of 98 patients) was reported with single-agent nivolumab. The median follow-up in this arm was 6.5 months, and the median duration of response was not reached. ORRs of 19% and 23% were reported in the two cohorts of nivolumab and ipilimumab combinations, respectively. Treatment-related AEs were higher in the combination arm than with nivolumab monotherapy.
PD-L1 expression on tumor and immune cells in tumor biopsies has been associated with increased clinical benefit from PD-1 and PD-L1 inhibition in various tumor types, including NSCLC.
14,15,19,27,28 The role of PD-L1 selection for pembrolizumab in patients with SCLC is currently unknown; this study only included patients with PD-L1-positive tumors. In a cross-trial comparison, the ORR from single-agent pembrolizumab in this study of PD-L1-expressing SCLC was 33.3% compared with the 10% ORR with nivolumab monotherapy in PD-L1-unselective patients with SCLC, which suggests that enrichment by PD-L1 selection may play a role in the observed increased response rate from pembrolizumab monotherapy. However, responses were also reported in PD-L1-negative patients who received nivolumab (CheckMate 032; ClinicalTrials.gov identifier: NCT01928394).
21
The discordance between two anti-PD-1 antibodies may be explained by the fact that, despite having the same target (anti-PD-1), these are two different antibodies with different potencies and binding affinities; this hypothesis is supported by the remarkably discordant results in the first-line treatment of patients with NSCLC.
29, 30 The ongoing KEYNOTE-158 trial (ClinicalTrials.gov identifier: NCT02628067) will evaluate pembrolizumab 200 mg every 3 weeks in patients with extensive-stage SCLC regardless of PD-L1 status in an attempt to better define the role of PD-L1 selection in these patients.
Other aspects of the tumor and the immune response directed against it are likely critical in the determination of the success of immune checkpoint blockade. Tumor CD8 + T-cell infiltration has been linked to antitumor activity in patients with advanced melanoma treated with pembrolizumab. 31 The number of tumor mutations, which encode neoepitopes, and which have been identified as key antigenic targets for tumor-specific T-cell responses, has been associated with clinical activity of PD-1 inhibition in NSCLC, colorectal cancer, and other tumors. [32] [33] [34] [35] Although there are limited data on the frequency of T-cell inflammation, SCLC is strongly associated with smoking and is one of the most highly mutated tumors within the spectrum of solid tumors. In both adenocarcinoma and squamous cell lung cancers (and several other cancers), the number of predicted antigenic mutations correlated with T-cell cytolytic activity, a potential surrogate for the presence of cytotoxic T cells in the tumor. 36 In addition to PD-L1 expression, the roles of other biomarkers, including gene expression profiles and mutational burdens, will be evaluated in KEYNOTE-158 (ClinicalTrials.gov identifier: NCT02628067).
Our trial enrolled a heterogeneous patient population with platinum-sensitive or platinum-resistant disease and a range of previous lines of therapy, with a majority receiving more than two prior lines of treatment. Unfortunately, data about platinum sensitivity were not collected prospectively, so it was difficult to make any inferences for activity of pembrolizumab in platinum-resistant jco.org versus -sensitive disease. Other limitations include the small number of patients and substantial patient selection as a result of the low PD-L1 positivity rate seen in SCLC. Regardless, the objective responses seen were robust and durable, consistent with the presumed mechanism of action of anti-PD-1 antibodies. 13 In summary, pembrolizumab demonstrated a favorable safety profile and promising durable clinical activity in pretreated patients with PD-L1-positive extensive-stage SCLC. Building on this initial safety and clinical efficacy signal, multiple trials were initiated with the aims to (1) better define biomarkers to more accurately define patients with SCLC who are likely to respond to pembrolizumab monotherapy (KEYNOTE-158; ClinicalTrials.gov identifier: NCT02628067) and (2) increase the efficacy of monotherapy by moving treatment with pembrolizumab to the front-line and maintenance settings, as well as to combinations with chemotherapy, radiotherapy, and other immune-modulating agents (ie, ClinicalTrials.gov identifiers: NCT02359019, NCT02551432, NCT02934503, and NCT02402920).
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